BioAtla, Inc. (NASDAQ:BCAB) Shares Bought by American Century Companies Inc.

American Century Companies Inc. grew its position in BioAtla, Inc. (NASDAQ:BCAB) by 36.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,391 shares of the company’s stock after purchasing an additional 11,503 shares during the quarter. American Century Companies Inc. owned about 0.09% of BioAtla worth $59,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in BCAB. Chase Investment Counsel Corp purchased a new position in BioAtla during the 1st quarter worth $263,000. Perceptive Advisors LLC purchased a new stake in shares of BioAtla during the fourth quarter worth about $180,000. PVG Asset Management Corp acquired a new position in shares of BioAtla during the fourth quarter valued at about $161,000. Acadian Asset Management LLC raised its position in shares of BioAtla by 57.6% in the 1st quarter. Acadian Asset Management LLC now owns 155,188 shares of the company’s stock valued at $532,000 after purchasing an additional 56,748 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in BioAtla in the 1st quarter worth approximately $103,000. 77.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, JMP Securities restated a “market outperform” rating and set a $5.00 price target on shares of BioAtla in a research note on Monday, September 16th.

BioAtla Stock Performance

Shares of BCAB opened at $2.20 on Friday. The stock has a 50-day moving average of $1.74 and a two-hundred day moving average of $2.06. The stock has a market cap of $105.86 million, a P/E ratio of -0.88 and a beta of 1.06. BioAtla, Inc. has a one year low of $1.14 and a one year high of $4.02.

BioAtla (NASDAQ:BCAB) last released its earnings results on Thursday, August 8th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. During the same period last year, the company posted ($0.75) EPS. Analysts predict that BioAtla, Inc. will post -1.52 EPS for the current fiscal year.

BioAtla Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.